Q3 EPS Estimate for Phibro Animal Health Boosted by Analyst

Key Points

• Zacks Research has increased its Q3 2026 earnings estimate for Phibro Animal Health Corporation from $0.66 to $0.69 per share, while maintaining a "Hold" rating on the stock.
• Phibro Animal Health reported Q2 earnings of $0.57 per share, exceeding analysts' expectations, along with revenues of $378.7 million compared to an anticipated $362.24 million.
• Institutional investors own 99.34% of Phibro Animal Health's stock, with significant activity seen from several funds increasing their stakes during the second quarter.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Zacks Research upped their Q3 2026 earnings estimates for shares of Phibro Animal Health in a research note issued on Friday, September 26th. Zacks Research analyst Team now anticipates that the company will earn $0.69 per share for the quarter, up from their prior forecast of $0.66. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's Q1 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.63 EPS and FY2027 earnings at $2.55 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. The firm had revenue of $378.70 million during the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Several other equities research analysts have also weighed in on PAHC. JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Morgan Stanley set a $34.00 target price on Phibro Animal Health in a research note on Thursday, August 28th. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research report on Monday, June 16th. Bank of America increased their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research note on Friday, August 29th. Finally, BNP Paribas raised Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and an average target price of $28.40.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $38.81 on Monday. The stock has a market cap of $1.57 billion, a P/E ratio of 32.89, a price-to-earnings-growth ratio of 1.15 and a beta of 0.88. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. The stock has a 50 day moving average of $33.67 and a 200-day moving average of $26.67. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $41.57.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PAHC. National Bank of Canada FI bought a new stake in shares of Phibro Animal Health in the first quarter worth about $30,000. Financial Management Professionals Inc. bought a new stake in shares of Phibro Animal Health in the second quarter worth about $32,000. EverSource Wealth Advisors LLC increased its holdings in shares of Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company's stock worth $69,000 after acquiring an additional 2,685 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company's stock worth $118,000 after acquiring an additional 4,079 shares in the last quarter. Finally, Curat Global LLC bought a new stake in shares of Phibro Animal Health in the first quarter worth about $146,000. Institutional investors own 99.34% of the company's stock.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 14,080 shares of the business's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $40.33, for a total value of $567,846.40. Following the transaction, the chief executive officer owned 45,400 shares of the company's stock, valued at approximately $1,830,982. The trade was a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 24,622 shares of company stock valued at $995,893 over the last quarter. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health's payout ratio is currently 40.68%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.